Jasper Therapeutics closes $103.5M public offering of 69M shares at $1.50/share

Jasper Therapeutics, Inc.

Closed underwritten offering of 69,000,000 shares at $1.50, including 9M option shares.
Gross proceeds of approximately $103.5M before underwriting discounts and expenses.
Offering made under effective shelf registration statement (File No. 333-267777) filed Oct 2022.
Lead book-running managers: Credit Suisse Securities and William Blair; Oppenheimer as passive book-runner.
Company focuses on c-Kit antibody therapies for chronic spontaneous urticaria, MDS, and transplant conditioning.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.